Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84

Futu News06:31 · Ratings

Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence

TipRanks05:45 · Ratings

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

GlobeNewswireJan 13 20:00

Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?

Seeking AlphaJan 12 04:06

Gene Editing Stocks Drop as Intellia Announces Layoffs

Seeking AlphaJan 11 02:29

OptionMetrics and CRSP Announce Partnership Giving Academic Researchers Increased Integration of U.S. Equities and Options Data in Research

BusinesswireJan 9 22:07